Depression in Dercum’s disease and in obesity: A case control study

BMC Psychiatry

Håkan Brorson¹  Henry Svensson¹  Emma Hansson¹ 

[1] Department of Clinical Sciences Malmö, Lund University, Plastic and Reconstructive Surgery, Skåne University Hospital, SE-205 02, Malmö, Sweden

关键词: MADRS;    Depression;    Obesity;    Chronic pain;    Adiposis dolorosa;    Dercum’s disease;   

Others  :  1124357
DOI  :  10.1186/1471-244X-12-74

 received in 2011-11-11, accepted in 2012-07-03,  发布年份 2012

【 摘 要 】

Background

Dercum’s disease is characterised by pronounced pain in the adipose tissue and a number of associated symptoms. The condition is usually accompanied by generalised weight gain. Many of the associated symptoms could also be signs of depression. Depression in Dercum’s disease has been reported in case reports but has never been studied using an evidence-based methodology. The aim of this study was to examine the presence of depression in patients with Dercum’s disease compared to obese controls that do not experience any pain.

Methods

A total of 111 women fulfilling the clinical criteria of Dercum’s disease were included. As controls, 40 obese healthy women were recruited. To measure depression, the Montgomery Åsberg Depression Rating Scale (MADRS) was used.

Results

According to the total MADRS score, less than half of the patients were classified as having “no depression” (44%), the majority had “light” or “moderate depression” (55%) and one individual had “severe depression” in the Dercum group. In the control groups, the majority of the patients were classified as having “no depression” (85%) and a small number had “light depression” (15%). There was a statistically significant difference for the total MADRS score between the two groups (p = 0.014).

Conclusion

The results indicate that the patients with Dercum’s disease are more likely to suffer from depression than controls.

【 授权许可】

   
2012 Hansson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Brorson H, Fagher B: Dercum’s disease. Fatty tissue rheumatism caused by immune defense reaction? Läkartidningen 1996, 93:1433-1436.
• [2]Roux J, Vitaut M: Maladie de Dercum (Adiposis dolorosa). Revue Neurol (Paris) 1901, 9:881-888.
• [3]Labbé M, Boulin R: Lipomatose douloureuse et maladie de Dercum. Bull Mem Soc Med Hop Paris 1927, 51:687-695.
• [4]Bair MJ, Robinson RL, Katon W, Kroenke K: Depression and pain comorbidity: a literature review. Arch Intern Med 2003, 163:2433-2445.
• [5]Robinson MJ, Edwards SE, Iyengar S, Bymaster F, Clark M, Katon W: Depression and pain. Front Biosci 2009, 14:5031-5051.
• [6]Moi L, Canu C, Pirari P, Mura MN, Piludu G, Del Giacco GS: Dercum’s disease: a case report. Ann Ital Med Int 2005, 20:187-191.
• [7]Hansson E, Svensson H, Brorson H: Liposuction may reduce pain in Dercum’s disease (Adiposis dolorosa). Pain Med 2011, 12:942-952.
• [8]Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
• [9]Svanborg P, Asberg M: A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J Affect Disord 2001, 64:203-216.
• [10]Anderberg UM, Marteinsdottir I, von Knorring L: Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Eur J Pain 2000, 4:27-35.
• [11]de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P: Depression and obesity: A meta-analysis of community-based studies. Psychiatry Res 2010, 178:230-235.
• [12]Petry NM, Barry D, Pietrzak RH, Wagner JA: Overweight and obesity are associated with psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2008, 70:288-297.
• [13]Walter SD: Berkson’s bias and its control in epidemiologic studies. J Chronic Dis 1980, 33:721-725.
• [14]Arnold LM, Crofford LJ, Martin SA, Young JP, Sharma U: The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007, 8:633-638.
• [15]Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50:2974-2984.
• [16]McEwen BS: Protective and damaging effects of stress mediators. N Engl J Med 1998, 338:171-179.
• [17]Hamilton NA, Catley D, Karlson C: Sleep and the affective response to stress and pain. Health Psychol 2007, 26:288-295.
• [18]Affleck G, Urrows S, Tennen H, Higgins P, Abeles M: Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain 1996, 68:363-368.
• [19]Gold AR, Dipalo F, Gold MS, Broderick J: Inspiratory airflow dynamics during sleep in women with fibromyalgia. Sleep 2004, 27:459-466.
• [20]Resta O, Foschino-Barbaro MP, Legari G, Talamo S, Bonfitto P, Palumbo A, Minenna A, Giorgino R, De Pergola G: Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord 2001, 25:669-675.